Skip to main content
    H

    Harmony Biosciences Holdings (HRMY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $32.96
    -0.80 (-2.37%)

    Market Cap: $1.94B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Harmony Biosciences Holdings (HRMY) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Harmony Biosciences Holdings (HRMY) has a market cap of $1.94B and an enterprise value of $1.44B. It holds $498.00M more cash than debt, 25.73% of its market cap.

    Total Valuation

    Enterprise value is 25.73% below the market cap, as cash exceeds debt.

    Market Cap$1.94B
    Enterprise Value$1.44B
    Latest price (Nov 17, 2026)$32.96

    Key Dates

    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.82% in the quarter ended Sep 30, 2026 and grew 1.34% a year over 2 years.

    Shares Outstanding58.41M
    Shares Change (YoY)+1.49%
    Shares Change (QoQ)+0.82%
    Share Count Growth (2Y CAGR)+1.34%

    Valuation Ratios

    Sales and book value multiples are 1.9x and 1.8x. Its year-end P/E ranged from 8.5x to 51.4x from 2021 to 2025.

    P/E Ratio9.6x
    Forward P/E8.6x
    P/S Ratio1.9x
    Forward P/S1.9x
    P/B Ratio1.8x
    P/TBV Ratio1.9x
    P/OCF Ratio6.0x
    PEG Ratio1.6

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 5.9x EBITDA.

    EV / Earnings8.0x
    EV / Sales1.5x
    EV / EBITDA5.9x

    Price Statistics

    The stock is down 3.88% over 52 weeks and trades 14.30% below its 50-day average.

    Beta (1Y)0.64
    52-Week Change-3.88%
    1-Month Change-13.15%
    3-Month Change-15.12%
    6-Month Change+10.49%
    5-Year Change-6.53%
    Total Return (1Y)-3.88%
    Total Return (3Y CAGR)+6.92%
    Total Return (5Y CAGR)-3.39%
    Return vs SPY (1Y)-14.59%
    Max Drawdown (1Y)-34.49%
    Max Drawdown (3Y)-37.58%
    Sharpe Ratio (1Y)-0.08
    Correlation with SPY (1Y)0.21
    50-Day Average$38.46
    200-Day Average$34.55
    52-Week Range$25.90 to $43.49
    RSI (14 Days)33.5
    Average Volume (20 Days)1.20M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.44x current liabilities, and total debt is 0.14x shareholder equity.

    Current Ratio3.44x
    Quick Ratio3.42x
    Debt / Equity0.14x
    Debt / EBITDA0.62x
    Interest Coverage16.95x

    Returns and Efficiency

    Return on invested capital is 13.73% over the last 12 months, against a 5-year average of 19.07%.

    Return on Equity (ROE)16.66%
    Return on Assets (ROA)12.08%
    Return on Invested Capital (ROIC)13.73%
    ROE (5Y Average)26.30%
    ROA (5Y Average)15.57%
    ROIC (5Y Average)19.07%
    Asset Turnover0.74x
    Inventory Turnover42.01x
    Receivables Turnover8.29x
    Cash Conversion Cycle18 days

    Taxes

    Income tax took 23.33% of pretax income over the last 12 months.

    Income Tax (TTM)$54.36M
    Effective Tax Rate23.33%

    Scores

    HRMY has an Altman Z-Score of 4.84, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score4.84
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $989.36M over the last 12 months is up 19.79% from the 12 months before.

    Revenue$989.36M
    Revenue Growth (YoY)+19.79%
    Gross Profit$732.42M
    Operating Income$219.36M
    Pretax Income$232.96M
    Net Income$178.60M
    EBITDA$241.59M
    Reported EPS (TTM)$3.45

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 72.30% of the $1.48B in total assets.

    Cash and Equivalents$647.10M
    Total Debt$149.10M
    Net Cash$498.00M
    Net Cash Per Share$8.53
    Working Capital$663.29M
    Shareholder Equity$1.07B
    Book Value Per Share$18.36
    Tangible Book Value$1.00B
    Tangible Book Per Share$17.13
    Total Assets$1.48B
    Total Liabilities$406.01M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow$323.04M
    FCF Per Share$5.55
    Depreciation and Amortization$22.83M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 22.17%, against a 5-year average of 27.96%.

    Gross Margin74.03%
    Operating Margin22.17%
    Pretax Margin23.55%
    Net Margin18.05%
    EBITDA Margin24.42%
    Gross Margin (5Y Average)79.43%
    Operating Margin (5Y Average)27.96%
    Net Margin (5Y Average)22.71%

    Growth

    Revenue grew 25.64% a year over 3 years, and EPS 5.89% a year.

    Revenue Growth (3Y CAGR)+25.64%
    Revenue Growth (5Y CAGR)+40.30%
    EPS Growth (3Y CAGR)+5.89%
    FCF Growth (3Y CAGR)+34.09%
    Operating Income Growth (3Y CAGR)+20.15%
    Book Value Per Share Growth (2Y CAGR)+36.69%
    Tangible Book Per Share Growth (2Y CAGR)+54.05%

    Revenue and profit by year

    Dividends and Yields

    HRMY does not pay a dividend.

    Earnings Yield10.42%
    Shareholder Yield0.00%

    Peer Position

    Against 5 similar companies, HRMY has the 5th highest P/S.

    P/S Ratio1.9x vs 5.1x median
    ROIC13.73% vs -28.99% median
    Revenue Growth (Trailing 4 Quarters, YoY)+19.79% vs -51.69% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 16.51% and EPS growth at 34.56% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+16.51%
    EPS Growth Forecast (2Y CAGR)+34.56%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About HRMY

    What is HRMY's market cap?

    Harmony Biosciences Holdings has a market cap of $1.94B. Its enterprise value, which adds debt and subtracts cash, is $1.44B.

    What is HRMY's P/E ratio?

    Harmony Biosciences Holdings has a trailing P/E ratio of 9.6x and a forward P/E of 8.6x.

    How many shares of HRMY are outstanding?

    Harmony Biosciences Holdings has 58.41M shares outstanding. The count is up 1.49% from a year earlier.

    Does HRMY pay a dividend?

    No. Harmony Biosciences Holdings does not pay a dividend.

    How much debt does HRMY have?

    Harmony Biosciences Holdings has $149.10M of total debt and $647.10M of cash and equivalents, a net cash position of $498.00M.